articleTop 1% cited
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Science Translational Medicine · 2016 · Vol. 8(362) · pp. 362ps17–362ps17
Yves Pommier✉(National Cancer Institute)Mark J. O’Connor(AstraZeneca (United Kingdom))Johann S. de Bono(Royal Marsden NHS Foundation Trust)
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP "trapping" and what this means for both clinical monotherapy and combination with chemotherapeutic agents.
PARP inhibition in cancer therapyDNA Repair MechanismsCancer therapeutics and mechanismsTrap (plumbing)Cancer cellPoly ADP ribose polymeraseAction (physics)Cancer researchChemistryCancerPharmacologyMedicineBiochemistry
MeSH terms
Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsBreast NeoplasmsDNA DamageDNA RepairEnzyme InhibitorsFemaleHumansMaleMutationNeoplasmsOvarian NeoplasmsPoly(ADP-ribose) PolymerasesProstatic NeoplasmsClinical Trials, Phase I as Topic
Funding
- Department of Health and Social Care
Citations
742
FWCI
27.11
field-weighted impact
References
79
Percentile
100%
vs. same field & year
Citations per year
References
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Cancer Research · 2012 · 2,130 citations
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Cancer Research · 2006 · 1,298 citations
Targeting the DNA Damage Response in Cancer
Molecular Cell · 2015 · 1,490 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.